Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 1, Supplement 1 , Pages S4-S6 , January 2008

Leon Thal and the therapeutic age of Alzheimer’s disease

  • Paul S. Aisen

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: 202-687-7337; Fax: 202-784-2261.

References 

  1. Mandel RJ, Thal LJ. Physostigmine improves water maze performance following nucleus basalis magnocellularis lesions in rats. Psychopharmacology (Berl). 1988;96:421–425
  2. Thal LJ, Dokla CP, Armstrong DM. Nucleus basalis magnocellularis lesions: lack of biochemical and immunocytochemical recovery and effect of cholinesterase inhibitors on passive avoidance. Behav Neurosci. 1988;102:852–860
  3. Dokla CP, Thal LJ. Effect of cholinesterase inhibitors on Morris water task behavior following lesions of the nucleus basalis magnocellularis. Behav Neurosci. 1988;102:861–871
  4. Mandel RJ, Chen AD, Connor DJ, Thal LJ. Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers. J Pharmacol Exp Ther. 1989;251:612–619
  5. Thal LJ, Rosen W, Sharpless NS, Crystal H. Choline chloride fails to improve cognition of Alzheimer’s disease. Neurobiol Aging. 1981;2:205–208
  6. Thal LJ, Fuld PA, Masur DM, Sharpless NS, Davies P. Oral physostigmine and lecithin improve memory in Alzheimer’s disease. Psychopharmacol Bull. 1983;19:454–456
  7. Thal LJ, Fuld PA, Masur DM, Sharpless NS. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol. 1983;13:491–496
  8. Thal LJ, Masur DM, Sharpless NS, Fuld PA, Davies P. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10:627–636
  9. Thal LJ, Masur DM, Blau AD, Fuld PA, Klauber MR. Chronic oral physostigmine without lecithin improves memory in Alzheimer’s disease. J Am Geriatr Soc. 1989;37:42–48
  10. Dokla CP, Parker SC, Thal LJ. Tetrahydroaminoacridine facilitates passive avoidance learning in rats with nucleus basalis magnocellularis lesions. Neuropharmacology. 1989;28:1279–1282
  11. Kwo-On-Yuen PF, Mandel R, Chen AD, Thal LJ. Tetrahydroaminoacridine improves the spatial acquisition deficit produced by nucleus basalis lesions in rats. Exp Neurol. 1990;108:221–228
  12. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. N Engl J Med. 1992;327:1253–1259
  13. Thal LJ. The Alzheimer’s Disease Cooperative Study in 2004. Alzheimer Dis Assoc Disord. 2004;18:183–185
  14. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med. 1997;336:1216–1222
  15. Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, et al. A multicenter evaluation of new treatment efficacy instruments for Alzheimer’s disease clinical trials: overview and general results. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S1–S12
  16. Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, et al. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord. 2006;20:S109–S123
  17. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141:1356–1364
  18. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease: the Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S33–S39
  19. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer’s Disease cooperative study: clinical global impression of change. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S22–S32
  20. Sano M, Zhu CW, Whitehouse PJ, Edland S, Jin S, Ernstrom K, et al. ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly. Alzheimer Dis Assoc Disord. 2006;20:S191–S202
  21. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. N Engl J Med. 2005;352:2379–2388
  22. Mulnard RA. Estrogen as a treatment for Alzheimer disease. JAMA. 2000;284:307–308
  23. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial of prednisone in Alzheimer’s disease: Alzheimer’s Disease Cooperative Study. Neurology. 2000;54:588–593
  24. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819–2826
  25. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, et al. The Alzheimer’s disease neuroimaging initiative. Neuroimaging Clin N Am. 2005;15:869–877xi–xii

PII: S1552-5260(07)00661-9

doi: 10.1016/j.jalz.2007.12.001

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 1, Supplement 1 , Pages S4-S6 , January 2008

Article Tools